Nothing Special   »   [go: up one dir, main page]

AR091024A1 - Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos - Google Patents

Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos

Info

Publication number
AR091024A1
AR091024A1 ARP130101638A ARP130101638A AR091024A1 AR 091024 A1 AR091024 A1 AR 091024A1 AR P130101638 A ARP130101638 A AR P130101638A AR P130101638 A ARP130101638 A AR P130101638A AR 091024 A1 AR091024 A1 AR 091024A1
Authority
AR
Argentina
Prior art keywords
factor
activated form
coagulation
antibodies
join
Prior art date
Application number
ARP130101638A
Other languages
English (en)
Inventor
Dr Buchmller Anja
Dr Grudzinska-Goebel Joanna
Dr Finnern Ricarda
Dr Schfer Martina
Dr Gerdes Christoph
Dr Jrien Hannah
Dr Wilmen Andreas
Straburger Julia
Dr Dittmer Frank
Dr Strerath Michael
Itakura Asako
Y Leung Philberta
Tucker Erik
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR091024A1 publication Critical patent/AR091024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a anticuerpos capaces de unirse con el factor XI de coagulación y/o a su forma activada, factor XIa, y a sus procedimientos de uso, en particular procedimientos de uso como agentes que inhiben la agregación plaquetaria y, así, inhiben la formación de trombos. Composición farmacéutica, ácido nucleico, vector y células huésped.
ARP130101638A 2012-05-10 2013-05-10 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos AR091024A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12167438 2012-05-10
EP12181697 2012-08-24
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30

Publications (1)

Publication Number Publication Date
AR091024A1 true AR091024A1 (es) 2014-12-30

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101638A AR091024A1 (es) 2012-05-10 2013-05-10 Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos

Country Status (25)

Country Link
US (4) US9783614B2 (es)
EP (2) EP2847228B1 (es)
JP (2) JP6348900B2 (es)
KR (1) KR102060376B1 (es)
CN (1) CN104684932B (es)
AR (1) AR091024A1 (es)
AU (2) AU2013258043B2 (es)
BR (1) BR112014027952B1 (es)
CA (1) CA2872926C (es)
DK (1) DK2847228T3 (es)
ES (1) ES2698950T3 (es)
HK (1) HK1207091A1 (es)
HR (1) HRP20181680T1 (es)
HU (1) HUE040580T2 (es)
IL (1) IL235238B (es)
LT (1) LT2847228T (es)
MX (1) MX362454B (es)
NZ (1) NZ701121A (es)
PL (1) PL2847228T3 (es)
RS (1) RS57889B1 (es)
SG (2) SG10201609322QA (es)
SI (1) SI2847228T1 (es)
TW (2) TWI644925B (es)
WO (1) WO2013167669A1 (es)
ZA (1) ZA201407784B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067660A2 (en) 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
IN2014CN02806A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
KR102060376B1 (ko) * 2012-05-10 2019-12-30 바이엘 파마 악티엔게젤샤프트 응고 인자 xi 및/또는 그의 활성화 형태 인자 xia에 결합할 수 있는 항체 및 그의 용도
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PE20150639A1 (es) 2012-10-12 2015-05-11 Bristol Myers Squibb Co Formas cristalinas de inhibidor del factor xia
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (es) 2014-01-31 2018-03-10
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EA201791527A1 (ru) 2015-01-02 2017-12-29 Дайэкс Корп. Биспецифические антитела против плазменного калликреина и фактора xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
JP7028471B2 (ja) * 2016-03-23 2022-03-02 プロティックス ビーヴイ 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MA45234A (fr) * 2016-06-14 2019-04-17 Adimab Llc Anticorps anti-facteur xi de coagulation
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
US20200054719A1 (en) * 2016-11-02 2020-02-20 Erik Ian Tucker E-we thrombin analog and fibrinolytic combination
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
IL316673A (en) * 2016-12-23 2024-12-01 Novartis Ag Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE
PL3570882T3 (pl) * 2017-01-19 2022-02-07 Bayer Pharma Aktiengesellschaft Nowa stabilna formulacja dla przeciwciał fxia
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
KR20200087236A (ko) 2017-11-22 2020-07-20 노파르티스 아게 항-인자 XI/XIa 항체에 대한 반전 결합제 및 이의 용도
JP7149721B2 (ja) 2018-03-26 2022-10-07 株式会社Pfu 情報処理装置、文字認識エンジン最適化方法及びプログラム
CN112543627A (zh) * 2018-07-05 2021-03-23 拜耳公司 新型稳定的高浓度抗FXIa抗体制剂
SG11202100418PA (en) * 2018-08-01 2021-02-25 Novo Nordisk As Improved procoagulant antibodies
CN112514286A (zh) 2018-08-07 2021-03-16 日本电信电话株式会社 光传输系统和传输模式选择方法
KR20210042352A (ko) * 2018-08-09 2021-04-19 상하이 베네마에 파머수티컬 코포레이션 항-인자 xi 항체
CA3113691A1 (en) * 2018-09-17 2020-03-26 Board Of Regents, The University Of Texas System Compositions and methods for treating bone injury
CA3117856A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CA3125303A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
JP2022528595A (ja) 2019-04-16 2022-06-15 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CN117487017A (zh) * 2020-07-02 2024-02-02 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
WO2024141099A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
EP1686127A1 (de) 1996-10-14 2006-08-02 Bayer HealthCare AG Neue Heterocyclylmethyl-substituierte Pyrazolderivate und ihre Verwendung zur Behandlung von Herz-Kreislauf-Erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
PE20081214A1 (es) 2006-08-18 2008-09-24 Novartis Ag Anticuerpo especifico prlr y sus usos
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
WO2009046274A1 (en) 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
WO2009067660A2 (en) 2007-11-21 2009-05-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
ES2702365T3 (es) * 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
PL2373691T3 (pl) * 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
BR112012030177B1 (pt) 2010-05-27 2019-08-27 Merck Sharp & Dohme composto ativador da guanilato ciclase solúvel, e, composição farmacêutica
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US9090610B2 (en) 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
MX348470B (es) 2011-09-02 2017-06-13 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas.
KR102060376B1 (ko) * 2012-05-10 2019-12-30 바이엘 파마 악티엔게젤샤프트 응고 인자 xi 및/또는 그의 활성화 형태 인자 xia에 결합할 수 있는 항체 및 그의 용도

Also Published As

Publication number Publication date
TW201811834A (zh) 2018-04-01
EP2847228B1 (en) 2018-07-25
JP2018148920A (ja) 2018-09-27
TWI644925B (zh) 2018-12-21
BR112014027952A2 (pt) 2019-07-09
AU2018200850B2 (en) 2019-09-19
IL235238A0 (en) 2014-12-31
US11046783B2 (en) 2021-06-29
BR112014027952B1 (pt) 2022-06-21
ZA201407784B (en) 2019-01-30
MX2014013568A (es) 2014-12-08
AU2018200850A1 (en) 2018-02-22
AU2013258043A1 (en) 2014-11-13
US20180112009A1 (en) 2018-04-26
AU2018200850C1 (en) 2020-03-12
AU2013258043B2 (en) 2017-11-30
US9783614B2 (en) 2017-10-10
MX362454B (es) 2019-01-18
SG11201406719UA (en) 2014-11-27
EP2847228A1 (en) 2015-03-18
US10221247B2 (en) 2019-03-05
TW201400504A (zh) 2014-01-01
US20150099298A1 (en) 2015-04-09
US20180051093A1 (en) 2018-02-22
CN104684932A (zh) 2015-06-03
HRP20181680T1 (hr) 2018-12-14
JP2015517305A (ja) 2015-06-22
PL2847228T3 (pl) 2019-03-29
CA2872926C (en) 2022-07-05
DK2847228T3 (en) 2018-11-19
KR20150008166A (ko) 2015-01-21
HUE040580T2 (hu) 2019-03-28
SG10201609322QA (en) 2017-01-27
CN104684932B (zh) 2019-03-12
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
ES2698950T3 (es) 2019-02-06
HK1207091A1 (en) 2016-01-22
NZ701121A (en) 2017-06-30
KR102060376B1 (ko) 2019-12-30
WO2013167669A1 (en) 2013-11-14
SI2847228T1 (sl) 2018-11-30
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
IL235238B (en) 2019-08-29
JP6348900B2 (ja) 2018-06-27
CA2872926A1 (en) 2013-11-14
LT2847228T (lt) 2018-11-12
EP3404045A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
WO2014205451A3 (en) Compositions and methods for modulation of target nucleic acids
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
NL301030I2 (nl) Sarolaner, desgewenst in de vorm van een zout; moxidectine; en pyrantel embonaat
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BR112017010303A2 (pt) anticorpos anti-cd47, métodos e usos
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
ECSP12012105A (es) Antídotos de Anticoagulantes
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
IN2015DN00636A (es)
CL2015003710A1 (es) Enlozador escindible por trombina con xten y usos del mismo
IN2015DN00634A (es)
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
BR112015002809A2 (pt) solução aceleradora adequada para formar um sistema redox com peróxidos, e composição de dois componentes
TWD165437S (zh) 人形玩具
ECSP13012997A (es) Antídotos anticoagulantes
AR085919A1 (es) Moleculas de union bioespecificas que se unen a ligando 4 de tipo delta (dii4) y angiopoyetina 2 (ang2)
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
HUE052490T2 (hu) Transzglutamináz 2 elleni antitestek

Legal Events

Date Code Title Description
FC Refusal